364 related articles for article (PubMed ID: 22417806)
1. Value of PET/CT and MR lymphography in treatment of prostate cancer patients with lymph node metastases.
Fortuin AS; Deserno WM; Meijer HJ; Jager GJ; Takahashi S; Debats OA; Reske SN; Schick C; Krause BJ; van Oort I; Witjes AJ; Hoogeveen YL; van Lin EN; Barentsz JO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):712-8. PubMed ID: 22417806
[TBL] [Abstract][Full Text] [Related]
2. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance lymphography-guided selective high-dose lymph node irradiation in prostate cancer.
Meijer HJ; Debats OA; Kunze-Busch M; van Kollenburg P; Leer JW; Witjes JA; Kaanders JH; Barentsz JO; van Lin EN
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):175-83. PubMed ID: 21075555
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases.
Budiharto T; Joniau S; Lerut E; Van den Bergh L; Mottaghy F; Deroose CM; Oyen R; Ameye F; Bogaerts K; Haustermans K; Van Poppel H
Eur Urol; 2011 Jul; 60(1):125-30. PubMed ID: 21292388
[TBL] [Abstract][Full Text] [Related]
5. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
Kitajima K; Murphy RC; Nathan MA; Froemming AT; Hagen CE; Takahashi N; Kawashima A
J Nucl Med; 2014 Feb; 55(2):223-32. PubMed ID: 24434294
[TBL] [Abstract][Full Text] [Related]
6. Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement.
Van den Bergh L; Lerut E; Haustermans K; Deroose CM; Oyen R; Isebaert S; Budiharto T; Ameye F; Mottaghy FM; Bogaerts K; Van Poppel H; Joniau S
Urol Oncol; 2015 Mar; 33(3):109.e23-31. PubMed ID: 25655681
[TBL] [Abstract][Full Text] [Related]
7. Target volume definition in high-risk prostate cancer patients using sentinel node SPECT/CT and 18 F-choline PET/CT.
Vees H; Steiner C; Dipasquale G; Chouiter A; Zilli T; Velazquez M; Namy S; Ratib O; Buchegger F; Miralbell R
Radiat Oncol; 2012 Aug; 7():134. PubMed ID: 22873771
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy.
Maurer T; Souvatzoglou M; Kübler H; Opercan K; Schmidt S; Herrmann K; Stollfuss J; Weirich G; Haller B; Gschwend JE; Schwaiger M; Krause BJ; Treiber U
Eur Urol; 2012 May; 61(5):1031-8. PubMed ID: 22196847
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging.
Heesakkers RA; Jager GJ; Hövels AM; de Hoop B; van den Bosch HC; Raat F; Witjes JA; Mulders PF; van der Kaa CH; Barentsz JO
Radiology; 2009 May; 251(2):408-14. PubMed ID: 19401573
[TBL] [Abstract][Full Text] [Related]
10. (11)C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients.
Picchio M; Berardi G; Fodor A; Busnardo E; Crivellaro C; Giovacchini G; Fiorino C; Kirienko M; Incerti E; Messa C; Gianolli L; Di Muzio N
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1270-9. PubMed ID: 24599378
[TBL] [Abstract][Full Text] [Related]
11. High occurrence of aberrant lymph node spread on magnetic resonance lymphography in prostate cancer patients with a biochemical recurrence after radical prostatectomy.
Meijer HJ; van Lin EN; Debats OA; Witjes JA; Span PN; Kaanders JH; Barentsz JO
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1405-10. PubMed ID: 21640507
[TBL] [Abstract][Full Text] [Related]
12. Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series.
Passoni NM; Suardi N; Abdollah F; Picchio M; Giovacchini G; Messa C; Freschi M; Montorsi F; Briganti A
Urol Oncol; 2014 Jan; 32(1):38.e9-16. PubMed ID: 23769269
[TBL] [Abstract][Full Text] [Related]
13. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms.
Schiavina R; Scattoni V; Castellucci P; Picchio M; Corti B; Briganti A; Franceschelli A; Sanguedolce F; Bertaccini A; Farsad M; Giovacchini G; Fanti S; Grigioni WF; Fazio F; Montorsi F; Rigatti P; Martorana G
Eur Urol; 2008 Aug; 54(2):392-401. PubMed ID: 18456393
[TBL] [Abstract][Full Text] [Related]
14. Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer.
Fodor A; Berardi G; Fiorino C; Picchio M; Busnardo E; Kirienko M; Incerti E; Dell'Oca I; Cozzarini C; Mangili P; Pasetti M; Calandrino R; Gianolli L; Di Muzio NG
BJU Int; 2017 Mar; 119(3):406-413. PubMed ID: 27104782
[TBL] [Abstract][Full Text] [Related]
15. Radiation Treatment of Lymph Node Recurrence from Prostate Cancer: Is 11C-Choline PET/CT Predictive of Survival Outcomes?
Incerti E; Fodor A; Mapelli P; Fiorino C; Alongi P; Kirienko M; Giovacchini G; Busnardo E; Gianolli L; Di Muzio N; Picchio M
J Nucl Med; 2015 Dec; 56(12):1836-42. PubMed ID: 26405166
[TBL] [Abstract][Full Text] [Related]
16. Use of [11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression.
Contractor K; Challapalli A; Barwick T; Winkler M; Hellawell G; Hazell S; Tomasi G; Al-Nahhas A; Mapelli P; Kenny LM; Tadrous P; Coombes RC; Aboagye EO; Mangar S
Clin Cancer Res; 2011 Dec; 17(24):7673-83. PubMed ID: 22038995
[TBL] [Abstract][Full Text] [Related]
17. PSMA-PET guided dose-escalated volumetric arc therapy (VMAT) for newly diagnosed lymph node positive prostate cancer: Efficacy and toxicity outcomes at two years.
Shakespeare TP; Eggert E; Wood M; Westhuyzen J; Turnbull K; Rutherford N; Aherne N
Radiother Oncol; 2019 Dec; 141():188-191. PubMed ID: 31668514
[TBL] [Abstract][Full Text] [Related]
18. Imaging prostate cancer lymph node metastases with a multimodality contrast agent.
Hall MA; Kwon S; Robinson H; Lachance PA; Azhdarinia A; Ranganathan R; Price RE; Chan W; Sevick-Muraca EM
Prostate; 2012 Feb; 72(2):129-46. PubMed ID: 21538422
[TBL] [Abstract][Full Text] [Related]
19. [11C]Acetate positron emission tomography-computed tomography imaging of prostate cancer lymph-node metastases correlated with histopathological findings after extended lymphadenectomy.
Schumacher MC; Radecka E; Hellström M; Jacobsson H; Sundin A
Scand J Urol; 2015 Feb; 49(1):35-42. PubMed ID: 25001948
[TBL] [Abstract][Full Text] [Related]
20. Head-to-Head Comparison of
Schilham MGM; Zamecnik P; Privé BM; Israël B; Rijpkema M; Scheenen T; Barentsz JO; Nagarajah J; Gotthardt M
J Nucl Med; 2021 Sep; 62(9):1258-1263. PubMed ID: 33517328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
